Poly(ADP-ribose) polymerase (PARP) inhibitors are used for targeted therapy for ovarian cancer with homologous recombination deficiency (HRD). The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.